Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Shrinkage of the cerebellum (cerebellar atrophy), Delayed speech and language development, Global developmental delay, and Corpus callosum atrophy; and very common findings: Brain atrophy, Hyporeflexia, and Axial hypotonia. 35 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 9 | Dystonia, Seizure, Brain atrophy |
EMC1 encodes ER membrane protein complex subunit 1 (993 aa). Part of the endoplasmic reticulum membrane protein complex (EMC) that enables the energy-independent insertion into endoplasmic reticulum membranes of newly synthesized membrane proteins. Highest expression in Cells Cultured fibroblasts (41.9 TPM) and Brain Cerebellar Hemisphere (18.2 TPM).
Cerebellar atrophy, visual impairment, and psychomotor retardation; is associated with mutations in the EMC1 gene on chromosome 1.
EMC1 is classified as a druggable target (Transporter category) with score 0.0.
Genetic testing for EMC1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features, 3 very common features, 10 common features.
No clinical trials have been registered for cerebellar atrophy, visual impairment, and psychomotor retardation;.
7 publications have been identified in PubMed for cerebellar atrophy, visual impairment, and psychomotor retardation;. Research spans Case Report / Case Series (43%), Basic Science / Preclinical (29%), and Epidemiology / Natural History (14%).
Nishi E (2026). [PMID: 41479428](https://pubmed.ncbi.nlm.nih.gov/41479428/). *Clinical case reports*. [Case Report / Case Series]
Rezaei Z (2026). [PMID: 41825724](https://pubmed.ncbi.nlm.nih.gov/41825724/). *European journal of medical genetics*. [Case Report / Case Series]
Tanaka T (2025). [PMID: 38767473](https://pubmed.ncbi.nlm.nih.gov/38767473/). *Neural regeneration research*. [Basic Science / Preclinical]
Kajiwara K (2025). [PMID: 41203069](https://pubmed.ncbi.nlm.nih.gov/41203069/). *European journal of medical genetics*. [Epidemiology / Natural History]
Barbieri E (2024). [PMID: 39024940](https://pubmed.ncbi.nlm.nih.gov/39024940/). *Cortex; a journal devoted to the study of the nervous system and behavior*. [Case Report / Case Series]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:12 PM UTC
Online Mendelian Inheritance in Man
Common questions about cerebellar atrophy, visual impairment, and psychomotor retardation;
Muscles |
7 |
Shrinkage of the cerebellum (cerebellar atrophy), Generalized hypotonia, Brain atrophy |
Arms and legs | 2 | Prominent fingertip pads, Limb hypertonia |
Head and neck | 2 | Short upper lip, Secondary microcephaly |
Eyes | 2 | Cerebral visual impairment, Damage to the optic nerve (optic atrophy) |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
Makio T (2024). [PMID: 39070058](https://pubmed.ncbi.nlm.nih.gov/39070058/). *Contact (Thousand Oaks (Ventura County, Calif.))*. [Basic Science / Preclinical]
Alzayed NT (2024). [PMID: 38784058](https://pubmed.ncbi.nlm.nih.gov/38784058/). *Neurology. Genetics*. [Gene Therapy / Novel Therapeutics]